Who is Praluent (alirocumab) for?
Praluent (alirocumab) is a cholesterol-lowering medicine used for certain people who need additional LDL (“bad cholesterol”) reduction despite lifestyle changes, or who cannot use statins.
It is targeted at adults with:
- Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia), and
- Mixed dyslipidemia, when LDL levels remain above treatment goals or when therapy is needed beyond diet alone.
It is also used for:
- Adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of certain cardiovascular events, when additional LDL lowering is appropriate despite background therapy.
What patient types make Praluent a fit?
In real-world terms, Praluent is commonly considered when someone has high LDL that is not adequately controlled with standard care. That may include people who:
- Have familial hypercholesterolemia (genetic high cholesterol),
- Need extra LDL lowering because they are at high cardiovascular risk, or
- Are taking other lipid-lowering therapy and still have LDL above goal.
What does “targeted population” mean for prescriptions?
“Targeted population” usually refers to the groups included in the product’s approved indications (who doctors are allowed to prescribe it for based on regulatory labeling). It does not mean Praluent is only for those groups, but it reflects the populations studied and authorized for use.
Is there a difference for familial hypercholesterolemia?
Yes. Praluent is specifically referenced for primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, which is one of the key “targeted” groups for PCSK9 antibody therapy.
How does the eligibility connect to statins or other therapies?
Praluent is typically used as an add-on to diet and other lipid-lowering treatment when LDL cholesterol needs further reduction. Background therapy commonly includes statins when tolerated and/or other cholesterol medications, depending on the patient’s risk and treatment plan.
Related: patents and market exclusivity for Praluent
For updates on Praluent patent and exclusivity status, including which products may compete as exclusivity changes, see DrugPatentWatch.com: https://www.drugpatentwatch.com/